Systemic Immune-Inflammation Index (SII) and NeutrophilLymphocyte Ratio (NLR) as a Promising Predictor for Advanced Stage Events during the Follow-Up Period in Hepato-Gastrointestinal Cancer Patients
Abstract
Background: Tumor microenvironment has shown the role of inflammation in its progressivity. The heterogeneity of prognosis at the same TNM stage makes it difficult to classify patients who are more at risk of developing advanced stages. This study aimed to provide a deeper insight into the potential of cheap inflammation markers based on the Systemic ImmuneInflammation Index (SII) and Neutrophil-Lymphocyte Ratio (NLR) to predict the advanced stage during the follow-up period in patients with hepato-gastrointestinal cancer.
Methods: Case-control research was conducted using 120 data of patients with hepatogastrointestinal cancer (Colorectal cancer (CRC), hepatocellular carcinoma (HCC), gastrointestinal stromal tumor (GIST), esophageal adenocarcinoma (EAC), pancreatic ductal adenocarcinoma (PDAC), cholangio carcinoma (CCA)) taken from patient medical records. The patients were divided into case and control groups based on the presence of advanced stage events during the follow-up period that were further classified by the NLR and SII value. The advanced-stage events were analyzed and compared between the two groups using Chi-Square and logistic regression analysis to perceive the predictive value of each ratio.
Results: Patients with advanced-stage hepato-gastrointestinal cancer had higher NLR and SII than patients without advanced stage (p < 0.001). The group of patients with advanced stages had an average NLR of 18.45 and an SII of 6588.13. The group of patients without advanced stages had an average NLR of 5.12 and SII of 1545.01. The cut-off value was determined using the ROC curve, for NLR was 6.48 (92.5% sensitivity and 71.2% specificity), and for SII was 2264.24 (92.5% sensitivity and 76.2% specificity).
Conclusions: NLR and SII are cheap markers and have considerable potential for predicting advanced stage during the follow-up period in patients with hepato-gastrointestinal cancer. SII is more accurate as a predictor than NLR. These tools can be very useful in identifying the high-risk patients among the same TNM stage.
Keywords
DOI: 10.33371/ijoc.v18i4.1186
Article Metrics


References
Arnold M, Abnet CC, Neale RE, Vignat J, Edward L. Arnold M, Abnet CC, Neale RE, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020;159(1):335-349.e15. 2021;159(1):335–49.
Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–72.
Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26-38.
Liu Y, Liu L. Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. Cancers (Basel). 2022;14(18).
He K, Si L, Pan X, Sun L, Wang Y, Lu J, et al. Preoperative Systemic Immune–Inflammation Index (SII) as a Superior Predictor of Long-Term Survival Outcome in Patients With Stage I–II Gastric Cancer After Radical Surgery. Front Oncol. 2022;12(February):1–15.
Wang Q, Zhu D. The prognostic value of systemic immune-inflammation index (SII) in patients after radical operation for carcinoma of stomach in gastric cancer. J Gastrointest Oncol. 2019;10(5):965–78.
Nøst TH, Alcala K, Urbarova I, Byrne KS, Guida F, Sandanger TM, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol. 2021;36(8):841–8.
Yan Q, Ertao Z, Zhimei Z, Weigang D, Jianjun P, Jianhui C, et al. Systemic immune-inflammation index (SII): A more promising inflammation-based prognostic marker for patients with synchronic colorectal peritoneal carcinomatosis. J Cancer. 2020;11(18):5264–72.
Naszai M, Kurjan A, Maughan TS. The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: A systematic review and meta-analysis. Cancer Med. 2021;10(17):5983–97.
Yang JJ, Hu ZG, Shi WX, Deng T, He SQ, Yuan SG. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis. World J Gastroenterol. 2015;21(9):2807–15.
Kim JH, Lee JY, Kim HK, Lee JW, Jung SG, Jung K, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer. World J Gastroenterol. 2017;23(3):505–15.
Wu X, Han R, Zhong Y, Weng N, Zhang A. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Cancer Cell Int. 2021;21(1):1–10.
Miyamoto R, Inagawa S, Sano N, Tadano S, Adachi S, Yamamoto M. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients. Eur J Surg Oncol. 2018;44(5):607–12.
Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M, et al. High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma. Ann Surg. 2021;273(3):532–41.
Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, et al. Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer. Sci Rep. 2019;9(1):1–9.
Shantanam S, MUELLER. Inflammation-Induced DNA Damage, Mutations and Cancer. Physiol Behav. 2018;176(1):139–48.
Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):1–8.
Ye H, De S. Inflammation and Cancer: Triggers, Mechanisms and Consequences. J Int Soc Burn Inj. 2017;43(5):909–32.
Khandia R, Munjal A. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol. 2020;119:199–245.
Lin BD, Hottenga JJ, Abdellaoui A, Dolan C V., De Geus EJC, Kluft C, et al. Causes of variation in the neutrophil-lymphocyte and platelet-lymphocyte ratios: A twin-family study. Biomark Med. 2016;10(10):1061–72.
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.